Roman Trawicki - Zoetis President
| ZTS Stock | USD 178.54 0.29 0.16% |
President
Mr. Roman Trawicki is Executive Vice President, President of Global Manufacturing and Supply of the Company since 2015.
| Age | 56 |
| Tenure | 9 years |
| Address | 10 Sylvan Way, Parsippany, NJ, United States, 07054 |
| Phone | 973 822 7000 |
| Web | https://www.zoetis.com |
Roman Trawicki Latest Insider Activity
Tracking and analyzing the buying and selling activities of Roman Trawicki against Zoetis stock is an integral part of due diligence when investing in Zoetis. Roman Trawicki insider activity provides valuable insight into whether Zoetis is net buyers or sellers over its current business cycle. Note, Zoetis insiders must abide by specific rules, including filing SEC forms every time they buy or sell Zoetis'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Roman Trawicki over a year ago Exercise or conversion by Roman Trawicki of 6402 shares of Zoetis subject to Rule 16b-3 |
Zoetis Management Efficiency
The company has Return on Asset of 0.1399 % which means that on every $100 spent on assets, it made $0.1399 of profit. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of 0.5005 %, implying that it generated $0.5005 on every 100 dollars invested. Zoetis' management efficiency ratios could be used to measure how well Zoetis manages its routine affairs as well as how well it operates its assets and liabilities. Return On Assets is likely to gain to 0.17 in 2024, whereas Return On Tangible Assets are likely to drop 0.12 in 2024. At this time, Zoetis' Intangible Assets are comparatively stable compared to the past year. Net Tangible Assets is likely to gain to about 336.9 M in 2024, whereas Non Current Assets Total are likely to drop slightly above 5.6 B in 2024.Similar Executives
| Found 5 records | PRESIDENT Age | ||
| Steven Perrin | Eledon Pharmaceuticals | 58 | |
| Wubin MBA | Connect Biopharma Holdings | 59 | |
| Stephen Machatha | Aldeyra | 47 | |
| Kelly Carranza | Acumen Pharmaceuticals | N/A | |
| James Doherty | Acumen Pharmaceuticals | 56 | |
Management Performance
Zoetis Inc Leadership Team
Elected by the shareholders, the Zoetis' board of directors comprises two types of representatives: Zoetis inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Zoetis. The board's role is to monitor Zoetis' management team and ensure that shareholders' interests are well served. Zoetis' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Zoetis' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Roman Trawicki, Executive Vice President and Presidentident of Global Manufacturing and Supply | ||
| Steven Frank, Vice Relations | ||
| Kristin Peck, Chief Executive Officer, Executive Vice President and Group President, U.S. Operations, Business Development and Strategy, Director | ||
| Wafaa Mamilli, Executive Vice President and Chief Information and Digital Officer | ||
| William Steere, Independent Director | ||
| Roxanne Lagano, Chief Human Resource Officer, Executive Vice President and Global Operations | ||
| Linda Rhodes, Independent Director | ||
| Timothy Bettington, Executive Vice President and President U.S. Operations | ||
| Ester Banque, Executive Operations | ||
| Frank DAmelio, Independent Director | ||
| Robert Scully, Independent Director | ||
| Sherry Pudloski, Executive Vice President - Corporate Affairs and Communications | ||
| Sanjay Khosla, Independent Director | ||
| William Price, VP Officer | ||
| Jamie Brannan, Executive Diagnostics | ||
| Catherine Knupp, Executive Vice President, President - Research and Development | ||
| Jeannette Astorga, Executive Officer | ||
| Michael McCallister, Non-Executive Independent Chairman of the Board | ||
| Paul Bisaro, Independent Director | ||
| Antoinette Leatherberry, Independent Director | ||
| Nick Ashton, Executive Supply | ||
| Willie Reed, Independent Director | ||
| William Dorsey, Vice Diagnostics | ||
| Rimma Driscoll, Commercial Strategy | ||
| Glenn David, Chief Financial Officer, Executive Vice President | ||
| Wetteny Joseph, Chief Financial Officer, Executive Vice President, Head of Business Development | ||
| Robert Kelly, Executive Vice President and President International Operations | ||
| J McFarland, Executive Vice President and Chief Medical Officer | ||
| Robert Polzer, Executive Vice President and Presidentident of Research and Development | ||
| Gregory Norden, Independent Director | ||
| Louise Parent, Independent Director | ||
| Heidi Chen, Executive Vice President General Counsel, Corporate Secretary | ||
| Abhay Nayak, Executive Vice President Head of Strategy and Accelerated Growth Businesses | ||
| Juan Alaix, Chief Executive Officer, Director |
Zoetis Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Zoetis a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | 0.5 | ||||
| Return On Asset | 0.14 | ||||
| Profit Margin | 0.27 % | ||||
| Operating Margin | 0.37 % | ||||
| Current Valuation | 86.42 B | ||||
| Shares Outstanding | 456.3 M | ||||
| Shares Owned By Insiders | 0.24 % | ||||
| Shares Owned By Institutions | 95.74 % | ||||
| Number Of Shares Shorted | 6.03 M | ||||
| Price To Earning | 43.89 X |
Pair Trading with Zoetis
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Zoetis position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Zoetis will appreciate offsetting losses from the drop in the long position's value.Moving against Zoetis Stock
| 0.42 | ANVS | Annovis Bio Earnings Call Today | PairCorr |
| 0.36 | PRGO | Perrigo Company Buyout Trend | PairCorr |
The ability to find closely correlated positions to Zoetis could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Zoetis when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Zoetis - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Zoetis Inc to buy it.
The correlation of Zoetis is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Zoetis moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Zoetis Inc moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Zoetis can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Zoetis Stock Analysis
When running Zoetis' price analysis, check to measure Zoetis' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Zoetis is operating at the current time. Most of Zoetis' value examination focuses on studying past and present price action to predict the probability of Zoetis' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Zoetis' price. Additionally, you may evaluate how the addition of Zoetis to your portfolios can decrease your overall portfolio volatility.